17:56 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Candida Mouse studies suggest inhibiting JNK1 could help treat Candida albicans infection. In a mouse model of C. albicans infection, knockout of JNK1 or two JNK1 inhibitor tool compounds decreased fungal burden and inflammation in...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Encephalitis Cell culture and mouse studies suggest inhibiting JNK1 or its substrate AP-1 could help treat the viral infection Japanese encephalitis (JE). In JE virus-infected human glioma and murine microglial cell lines, a JNK inhibitor...
07:00 , Aug 18, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Diabetes; liver failure c-Jun N-terminal kinase (JNK) In vitro and mouse studies...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Marfan syndrome MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase...
07:00 , Aug 16, 2010 |  BC Week In Review  |  Company News

PregLem, Merck KGaA deal

Merck's Merck Serono S.A. unit granted PregLem exclusive, worldwide rights to develop and commercialize bentamapimod. Merck will receive an upfront payment and is eligible for milestones and royalties. PregLem said it plans to...